AndroGel Microdosing Protocols: What the Evidence Actually Shows

What Is AndroGel and How Does It Work?

AndroGel delivers testosterone transdermally through a hydroalcoholic gel vehicle applied once daily to the shoulders, upper arms, or abdomen. Absorption is passive and continuous, producing a relatively steady serum testosterone profile compared with weekly injections. The FDA-approved prescribing information for AndroGel 1.62% documents a mean steady-state total testosterone of approximately 500 ng/dL at the 40.5 mg/day starting dose in the key Phase 3 trial.

Pharmacokinetics at Standard Doses

Testosterone from AndroGel 1.62% reaches steady state within 24 hours of the first application. The drug's half-life after absorption is roughly 70 minutes, but the transdermal depot in the stratum corneum extends effective duration across 24 hours [1]. Peak serum levels (Cmax) occur approximately 2 hours after application, and the ratio of Cmax to Ctrough is generally less than 1.5, which is far more physiologic than the supraphysiologic peaks seen with testosterone cypionate injections.

Why the Dose Range Matters

The FDA label for AndroGel 1.62% specifies three dose steps: 20.25 mg, 40.5 mg, and 81 mg per day [1]. That 20.25 mg floor is not arbitrary. It corresponds to the minimum pump actuation volume that can be reliably dispensed and absorbed. Attempting doses below 20.25 mg using the standard pump introduces significant dose-measurement error.

What Does "Microdosing" Mean in This Context?

"Microdosing" has no single agreed definition in andrology. Physicians using the term for testosterone gel generally mean one of three things: (1) using the lowest labeled dose, 20.25 mg/day, in men whose hypogonadism is mild or borderline; (2) applying gel on alternate days rather than daily to reduce total weekly exposure; or (3) using small daily doses in transgender women or gender-diverse patients to achieve low-normal male or mid-female testosterone ranges. Each scenario has a different evidence base.

Scenario 1: Lowest Labeled Dose in Mild Hypogonadism

Men with total testosterone between 200 and 300 ng/dL and moderate symptom burden represent a reasonable population for starting at 20.25 mg/day. A 2006 pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism found that dose-response for serum testosterone is approximately linear across the 20.25-to-81 mg range, supporting the idea that 20.25 mg will raise serum T by roughly 100-150 ng/dL above baseline in most men. That increment may be sufficient for men with baseline levels of 250 ng/dL.

Scenario 2: Alternate-Day Dosing

No published RCT has tested alternate-day AndroGel dosing in men. Pharmacokinetically, total testosterone drops measurably within 36-48 hours of stopping topical testosterone, as shown in washout data from the T-Trials (N=788). This suggests alternate-day dosing would produce meaningful fluctuations in serum T, potentially recreating the symptom variability patients are trying to avoid. Until a trial demonstrates clinical non-inferiority, daily application at the lowest sufficient dose is the more defensible approach.

Scenario 3: Off-Label Gender-Affirming Use

Gender-affirming protocols for testosterone suppression in transgender women sometimes involve very low-dose topical testosterone to maintain libido without masculinization. These protocols are entirely off-label for AndroGel and are guided by expert consensus rather than RCT data. The World Professional Association for Transgender Health Standards of Care v8 acknowledges individualized dosing but does not specify AndroGel as a preferred agent for this purpose.

The T-Trials: Best Available Evidence for Topical Testosterone

The Testosterone Trials (T-Trials) remain the largest and most rigorous dataset for topical testosterone in older men. Published in the New England Journal of Medicine in 2016, the coordinated network of seven trials enrolled 788 men aged 65 or older with total testosterone below 275 ng/dL and at least one symptom domain.

Trial Design and Dosing Protocol

Participants received testosterone gel 1% titrated to achieve a serum testosterone level of 500-1000 ng/dL. The starting dose was 5 g/day (50 mg testosterone). Doses were adjusted at weeks 2 and 6 based on midmorning serum testosterone, with the range spanning 2.5 g/day to 10 g/day. This structured titration produced a mean serum testosterone of approximately 500 ng/dL in the treatment group versus 230 ng/dL in the placebo group [2].

Efficacy Findings Relevant to Dosing

Sexual function improved significantly in the treatment arm: the sexual activity score increased by 1.93 points on the Psychosexual Daily Questionnaire versus 0.44 in the placebo arm (P<0.001) [2]. Physical function measured by 6-minute walk distance did not improve significantly. Bone mineral density did improve in the testosterone arm in the bone trial. These outcome patterns matter for microdosing discussions because the sexual function signal emerged at mean levels around 500 ng/dL, not at supraphysiologic concentrations.

What the T-Trials Do Not Tell Us

The T-Trials were not designed to find a minimum effective testosterone concentration. They tested one target range (500-1000 ng/dL) against placebo. Men whose testosterone was titrated to only 350-450 ng/dL were not analyzed as a separate subgroup in the primary publications. This gap in the literature is precisely where the concept of microdosing is most clinically relevant and least supported by data.

FDA Label Guidance on Titration

The AndroGel 1.62% prescribing information provides explicit titration instructions that function as the closest evidence-based framework available for lower-dose approaches.

Step-Down Protocol Per Label

The label instructs clinicians to measure serum testosterone 14 days after initiation and again at 90 days, with dose adjustment based on the result:

• If serum T exceeds 1050 ng/dL at 14 days, decrease from 40.5 mg to 20.25 mg.
• If serum T is below 350 ng/dL at 14 days and the patient tolerates the drug, increase to 60.75 mg or 81 mg.
• Maintain the dose that keeps serum T in the 400-1050 ng/dL range [1].

A clinician choosing to start at 20.25 mg rather than 40.5 mg applies the same 14-day recheck logic. The label does not prohibit this approach, but it is off-label because the label describes 40.5 mg as the starting dose.

Measurement Timing

All serum testosterone measurements should be taken 2-8 hours after application and at least 14 days after the last dose change [1]. Drawing a level at a different time introduces error that can mimic under- or over-treatment. A sample collected 12 hours post-application may read 30-40% lower than a sample at 2 hours due to diurnal variation layered on top of the transdermal absorption curve, as documented in pharmacokinetic modeling published in Clinical Pharmacokinetics.

Building a Practical Microdosing Framework

Below is a clinical decision pathway for physicians considering a lower-than-standard starting dose of AndroGel 1.62%, synthesized from FDA labeling, T-Trials methodology, and pharmacokinetic literature. This framework has not been validated in an RCT and should be reviewed with the treating physician.

Patient Selection Criteria

A lower starting dose may be considered when:

• Baseline total testosterone is 200-300 ng/dL (confirmed on two morning samples per the Endocrine Society 2018 guidelines).
• Symptom burden is mild to moderate on the ADAM questionnaire or AMS scale.
• The patient has a hematocrit of 48-50% at baseline, where the erythrocytosis risk of full-dose therapy is meaningful.
• Fertility preservation is a concern, since even the 20.25 mg dose suppresses LH and FSH measurably [3].
• The patient weighs <70 kg, where standard doses may over-shoot the therapeutic window.

Proposed Lower-Dose Titration Schedule

| Week | Dose (AndroGel 1.62%) | Lab Draw | |------|-----------------------|----------| | 0 | 20.25 mg/day | Baseline total T, hematocrit, PSA | | 2 | 20.25 mg/day | Midmorning total T (2-8 h post-application) | | 6 | Adjust if <350 or >700 ng/dL | Total T, hematocrit | | 12 | Stable or re-adjust | Total T, PSA, hematocrit | | 26 | Annual rhythm established | Full panel |

The target range in this protocol is 400-700 ng/dL, narrower than the FDA's 400-1050 ng/dL, to reduce erythrocytosis and sleep apnea risk while capturing most of the symptomatic benefit demonstrated in the T-Trials.

Monitoring Parameters

Track hematocrit every 3-6 months for the first year. The Endocrine Society Clinical Practice Guideline recommends withholding or dose-reducing testosterone if hematocrit exceeds 54%. PSA should be measured at 3 and 12 months, then per age-appropriate prostate cancer screening guidelines from the American Cancer Society. Blood pressure, lipid panel, and bone density (at baseline if osteoporosis risk is present) round out the safety profile.

Absorption Variability and Its Clinical Implications

Topical testosterone has a coefficient of variation for peak serum levels of approximately 30-40%, as documented in a pharmacokinetic study of 29 healthy men published in the Journal of Clinical Pharmacology. This inter-individual variability is higher than with intramuscular injections and means that two men applying the same 20.25 mg dose may achieve serum testosterone levels differing by 150 ng/dL or more. Microdosing strategies therefore depend heavily on lab monitoring rather than on fixed dose recommendations.

Factors That Alter Absorption

Skin hydration, application site thickness, ambient temperature, and individual skin permeability all influence absorption. A 2004 study in Skin Pharmacology and Physiology found that application to the abdomen produced approximately 19% higher bioavailability than application to the upper arms in the same subjects. For patients on lower doses, instructing consistent site selection at every application reduces variability.

Transfer Risk at Lower Doses

Secondary exposure to partners or children remains a concern even at 20.25 mg. The FDA added a black-box warning for secondary exposure after case reports of virilization in children whose fathers used testosterone gel [1]. Covering the application site with clothing after the gel dries and washing hands thoroughly reduces transfer risk. Transfer risk does not disappear at lower doses, though it may be proportionally lower.

Testosterone Gel Versus Injections for Lower-Dose Therapy

Some clinicians prefer testosterone cypionate at lower doses (50-75 mg weekly rather than the standard 100-200 mg) as an alternative to gel microdosing, citing more predictable pharmacokinetics. A 2020 comparative pharmacokinetic analysis in Andrology found that weekly low-dose subcutaneous testosterone cypionate (50 mg) produced mean steady-state total T of approximately 420 ng/dL with a coefficient of variation of about 18%, lower than the 30-40% seen with gel. The tradeoff is that injections require either self-injection or office visits, and the Cmax-to-Ctrough ratio remains higher than with daily gel, even at weekly frequency.

For men who prioritize steady diurnal testosterone levels, the gel's continuous absorption profile is a genuine advantage even at lower doses. For men who struggle with daily application adherence, low-dose injectable protocols may produce more consistent results.

Special Populations and Microdosing Considerations

Older Men

The T-Trials cohort (mean age 72) showed that dose requirements to reach 500 ng/dL were similar to those in younger hypogonadal men, but erythrocytosis risk was higher. The T-Trials cardiovascular sub-trial found a non-significant trend toward increased coronary artery noncalcified plaque volume in the testosterone arm, which has fueled debate about cardiovascular safety in men over 65. A conservative approach of targeting 400-500 ng/dL rather than the upper end of the normal range is reasonable in men over 70.

Men With Borderline Baseline Testosterone

The Endocrine Society guideline states: "We suggest against making a diagnosis of androgen deficiency and initiating testosterone therapy in men with total testosterone levels >400 ng/dL." Men in the 300-400 ng/dL range with symptoms occupy a clinical gray zone where a therapeutic trial at the lowest labeled dose, monitored carefully, is a defensible off-label strategy. The 20.25 mg dose in such men may raise total testosterone by only 80-120 ng/dL, keeping them comfortably below any supraphysiologic threshold.

Men Concerned About Fertility

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis at any dose. LH and FSH suppression begins within days of starting testosterone gel, as shown in a gonadotropin kinetics study published in Fertility and Sterility. Men who want to preserve fertility should use clomiphene citrate or human chorionic gonadotropin (hCG) rather than exogenous testosterone, regardless of dose. The idea that a low dose of testosterone gel preserves fertility is not supported by the pharmacodynamic literature.

Practical Application Instructions

Correct application technique affects both efficacy and safety at any dose. The FDA label specifies:

1. Apply to clean, dry, intact skin of the shoulders and upper arms (1.62% formulation).
2. Allow the gel to dry completely before dressing, typically 3-5 minutes.
3. Wash hands with soap and water immediately after application.
4. Do not shower or swim for at least 2 hours after application [1].

At 20.25 mg (one pump actuation of the 1.62% formulation), the application volume is small. Patients should be shown a demonstration pump to understand the correct amount. Under-application or gel loss due to sweating within 2 hours of application will reduce absorbed dose unpredictably.